Zomedica R&D Spending Growth & History (ZOMDF)
Zomedica's r&d spending was $7.2M for fiscal 2025.
View full Zomedica company overviewZomedica annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.2M | −$102,000 | −1.40% |
| 2024 | 2024-12-31 | $7.3M | $1.5M | +26.53% |
| 2023 | 2023-12-31 | $5.7M | $3.2M | +122.81% |
| 2022 | 2022-12-31 | $2.6M | $905,000 | +54.09% |
| 2021 | 2021-12-31 | $1.7M | −$6.4M | −79.20% |
| 2020 | 2020-12-31 | $8.0M | −$2.3M | −22.25% |
| 2019 | 2019-12-31 | $10.3M | $28,138 | +0.27% |
| 2018 | 2018-12-31 | $10.3M | $7.6M | +274.99% |
| 2017 | 2017-12-31 | $2.8M | $1.2M | +81.18% |
| 2016 | 2016-12-31 | $1.5M | — | — |
Zomedica quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.1M | −$816,000 | −43.27% |
| Q1 2026 | 2026-03-31 | $1.2M | −$699,000 | −37.72% |
| Q4 2025 | 2025-12-31 | $1.6M | −$503,000 | −23.44% |
| Q3 2025 | 2025-09-30 | $1.8M | −$61,000 | −3.31% |
| Q2 2025 | 2025-06-30 | $1.9M | $380,000 | +25.23% |
| Q1 2025 | 2025-03-31 | $1.9M | $82,000 | +4.63% |
| Q4 2024 | 2024-12-31 | $2.1M | −$954,000 | −30.77% |
| Q3 2024 | 2024-09-30 | $1.8M | $978,000 | +112.80% |
| Q2 2024 | 2024-06-30 | $1.5M | $647,000 | +75.32% |
| Q1 2024 | 2024-03-31 | $1.8M | $853,000 | +92.92% |
| Q4 2023 | 2023-12-31 | $3.1M | $2.4M | +347.33% |
| Q3 2023 | 2023-09-30 | $867,000 | −$348,000 | −28.64% |
| Q2 2023 | 2023-06-30 | $859,000 | $540,000 | +169.28% |
| Q1 2023 | 2023-03-31 | $918,000 | $567,000 | +161.54% |
| Q4 2022 | 2022-12-31 | $693,000 | −$8,000 | −1.14% |
| Q3 2022 | 2022-09-30 | $1.2M | $926,000 | +320.42% |
| Q2 2022 | 2022-06-30 | $319,000 | $48,000 | +17.71% |
| Q1 2022 | 2022-03-31 | $351,000 | −$61,000 | −14.81% |
| Q4 2021 | 2021-12-31 | $701,000 | −$102,551 | −12.76% |
| Q3 2021 | 2021-09-30 | $289,000 | −$2.4M | −89.30% |
| Q2 2021 | 2021-06-30 | $271,000 | −$3.6M | −93.07% |
| Q1 2021 | 2021-03-31 | $412,000 | −$218,066 | −34.61% |
| Q4 2020 | 2020-12-31 | $803,551 | $13,605 | +1.72% |
| Q3 2020 | 2020-09-30 | $2.7M | $1.7M | +180.75% |
| Q2 2020 | 2020-06-30 | $3.9M | $2.8M | +268.17% |
| Q1 2020 | 2020-03-31 | $630,066 | −$6.9M | −91.63% |
| Q4 2019 | 2019-12-31 | $789,946 | −$5.8M | −87.94% |
| Q3 2019 | 2019-09-30 | $962,463 | $332,092 | +52.68% |
| Q2 2019 | 2019-06-30 | $1.1M | −$1.5M | −58.12% |
| Q1 2019 | 2019-03-31 | $7.5M | $6.9M | +1154.52% |
| Q4 2018 | 2018-12-31 | $6.6M | $5.4M | +462.32% |
| Q3 2018 | 2018-09-30 | $630,371 | $164,876 | +35.42% |
| Q2 2018 | 2018-06-30 | $2.5M | $2.0M | +402.67% |
| Q1 2018 | 2018-03-31 | $600,341 | −$16,108 | −2.61% |
| Q4 2017 | 2017-12-31 | $1.2M | — | — |
| Q3 2017 | 2017-09-30 | $465,495 | — | — |
| Q2 2017 | 2017-06-30 | $504,235 | — | — |
| Q1 2017 | 2017-03-31 | $616,449 | — | — |
Zomedica r&d spending trends
Over the last five fiscal years, Zomedica's r&d spending decreased from $8.0M to $7.2M, a change of −$877,891. The latest reported quarter, Q2 2026, shows $1.1M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Zomedica source filings ↗